logo
Plus   Neg
Share
Email

Aerpio Pharma: TIME-2b Study With AKB-9778 Fails To Meet Primary Endpoint

Aerpio Pharmaceuticals, Inc. (ARPO) announced top-line results from the company's TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy. The company said the administration of AKB-9778 twice daily did not meet the study's primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score compared to placebo.

AKB-9778 did show encouraging data in a number of prespecified, key secondary endpoints, consistent with the observations in the prior Phase 2a trial, the company noted. AKB-9778 was found to be safe and well-tolerated in the patient population through 48 weeks of twice-daily dosing.

"While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial. We and our clinical advisors believe that collectively these data support a potentially important role of the Tie2 pathway for the treatment of diabetic complications, as well as for open angle glaucoma. After a full analysis of the study data, we plan to provide an update on the status of the NPDR program," said Stephen Hoffman, CEO of Aerpio.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google announced a new $600 million investment for the expansion of Mayes County data center. The tech giant had started the data center in 2007 and expanded three times already. The new investment will add 100 jobs to Pryor community, Google CEO Sundar Pichai said during the announcement. In... King Arthur Flour, Inc. voluntarily recalled certain lots of 5 lb. Unbleached All-Purpose Flour due to the potential presence of Escherichia coli bacteria (E. coli), The U.S. Food and Drug Administration (FDA) stated. The company announced it is recalling 14,218 cases of the potentially affected lots that were distributed through retailers and distributors nationwide. Burger King has launched a new Upside Down Whopper in celebration of the third season of Netflix series "Stranger Things." The hamburger chain, in partnership with Netflix, announced it will start selling an Upside Down Whopper sandwich, which is just a regular Whopper served upside down, from June...
Follow RTT